MDxHealth SA Ordinary Shares (MDXH) Stock Price
MDXHStock
$0.21−94.89%52W
Market Cap$19.71M
P/E—
PEG Ratio—
Div yield—
Beta0.79
MDXH Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-100.80%
Price vs S&P 500 (4W)-64.24%
VGM Score34.97
MDXH Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.19 | -$0.18 | +7.22%(+$0.01) | |
| Q1 2026 | -$0.15 | -$0.17 | -11.84%(-$0.02) | |
| Q4 2025 | -$0.13 | -$0.17 | -33.33%(-$0.04) | |
| Q3 2025 | -$0.11 | -$0.16 | -48.15%(-$0.05) | |
| Q2 2025 | -$0.12 | -$0.14 | -12.90%(-$0.02) |
MDXH Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.17
4.00
4.00
4.00
Industry Peers — Health Services(30)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
MDXHMDxHealth SA Ordinary Shares | C | D | F | — | -5.2% | -16.6% | -305.0% | $0.21 |
| NTRANatera, Inc. Common Stock | F | A | A | — | 37.8% | -10.7% | -11.7% | $393.44 |
| DGXQuest Diagnostics Inc. | C | D | B | 26.1x | 9.9% | 14.1% | 14.5% | $235.00 |
| LHLabcorp Holdings Inc. | C | D | B | 29.4x | 6.4% | 10.4% | 11.6% | $317.95 |
| GHGuardant Health, Inc. Common Stock | F | A | B | — | 42.7% | -40.2% | -246.6% | $158.60 |
| CAICaris Life Sciences, Inc. Common Stock | F | A | B | — | 38.5% | 12.7% | 18.8% | $30.56 |
| RDNTRadNet, Inc. Common Stock | D | C | C | 1779.3x | 18.9% | 3.0% | -1.9% | $68.80 |
| GRALGRAIL, Inc. Common Stock | D | B | B | — | 23.1% | -338.4% | -15.9% | $117.81 |
| BLLNBillionToOne, Inc. Class A Common Stock | F | F | C | 621.1x | — | 10.9% | 8.9% | $98.12 |
| VCYTVeracyte, Inc. | D | B | C | 52.2x | 17.3% | 19.6% | 8.6% | $43.12 |
| CDNACareDx, Inc. | D | B | A | 18.3x | 34.4% | 23.6% | 32.8% | $64.00 |
About MDxHealth SA Ordinary Shares
MDxHealth SA develops molecular diagnostic tests for cancer using proprietary genomic and epigenetic technologies. Its tests help physicians diagnose urologic cancers and predict treatment response and recurrence risk. The company generates revenue through clinical laboratory services and by licensing its DNA methylation platform to partners. It operates in the United States and Europe.